AXERT Early miGraine Intervention Study (AEGIS): efficacy and safety of almotriptan malate (AXERT) versus placebo for the acute treatment of migraine headache

Trial Profile

AXERT Early miGraine Intervention Study (AEGIS): efficacy and safety of almotriptan malate (AXERT) versus placebo for the acute treatment of migraine headache

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2009

At a glance

  • Drugs Almotriptan (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms AEGIS
  • Most Recent Events

    • 23 Aug 2007 The expected completion date for this trial is now 1 Jun 2005.
    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top